Immuneering (IMRX)
(Delayed Data from NSDQ)
$3.43 USD
+0.06 (1.78%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $3.44 +0.01 (0.29%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Immuneering Corporation's dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
IMRX 3.43 +0.06(1.78%)
Will IMRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMRX
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
IMRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IMRX
Immuneering (IMRX) Jumps After Securing U.S. Patent for Cancer Drug
Immuneering rises on U.S. patent grant for atebimetinib
Immuneering (IMRX) Secures Patent for Cancer Drug Atebimetinib | IMRX Stock News
Immuneering granted atebimetinib patent by USPTO
Insider Buying: Thomas Schall Acquires Additional Shares of Immuneering Corp (IMRX)